Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 MG QD to Placebo as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Vildagliptin is an oral anti-diabetic agent. This is a 24-week study to assess the efficacy on HbA1c of 100 mg vildagliptin once daily as compared to placebo as add-on to metformin in patients with type 2 diabetes inadequately controlled with metformin.
Age
18 - 78 years
Sex
ALL
Healthy Volunteers
No
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
Novartis Investigative Site
Investigative Centers, Germany
Start Date
May 1, 2006
Primary Completion Date
November 1, 2007
Last Updated
November 18, 2016
370
ACTUAL participants
Vildagliptin AM
DRUG
vildagliptin pm
DRUG
placebo
DRUG
Lead Sponsor
Novartis Pharmaceuticals
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062